Guardian Pharmacy Services Inc. (GRDN)
NYSE NYSE Primary 
Guardian Pharmacy Services (GRDN) Q3 Earnings and Revenues Surpass Estimates
Guardian Pharmacy Services (GRDN) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to a loss of $2 per share a year ago.
Guardian Pharmacy Services, Inc. (GRDN) Q3 2025 Earnings Call Transcript
Guardian Pharmacy Services, Inc. ( GRDN ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Ashley Stockton - Head of Investor Relations & Senior Director Fred Burke - CEO, President & Director David Morris - CFO, Executive VP & Director Conference Call Participants John Ransom - Raymond James & Associates, Inc., Research Division David MacDonald - Truist Securities, Inc., Research Division Raj Kumar - Stephens Inc., Research Division Presentation Operator Good day, everyone, and welcome to Guardian Pharmacy's Third Quarter Earnings Call. [Operator Instructions] I will now hand the call over to Ashley Stockton.
Guardian Pharmacy Services (GRDN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Guardian Pharmacy (GRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Guardian Pharmacy Services, Inc. (GRDN) Presents at Jefferies 2025 Healthcare Services Conference Transcript
Guardian Pharmacy Services, Inc. (NYSE:GRDN ) Jefferies 2025 Healthcare Services Conference September 30, 2025 4:35 PM EDT Company Participants Fred Burke - CEO, President & Director Conference Call Participants Brian Tanquilut - Jefferies LLC, Research Division Presentation Brian Tanquilut Jefferies LLC, Research Division Good afternoon, and we're here for our last presentation of the day, but saving the best for last, right? So we have a Guardian Pharmacy Services as our next presenter.
Guardian Pharmacy (GRDN) Upgraded to Buy: What Does It Mean for the Stock?
Guardian Pharmacy (GRDN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Newly Listed Guardian Pharmacy Is Well Positioned In Highly Fragmented Market, Analyst Initiates With Buy Rating
Truist Securities has initiated coverage on Guardian Pharmacy Services, Inc GRDN, which operates long-term care pharmacies that facilitate the full lifecycle of pharmacy administration and associated consultative services for residents of long-term healthcare facilities (LTCFs).
Guardian Pharmacy shares rise 3% in lukewarm NYSE debut
Guardian Pharmacy's shares rise 3.3% in their NYSE debut, giving the healthcare firm a market valuation of about $880 million.
Healthcare firm Guardian Pharmacy raises $112 mln in US IPO
Guardian Pharmacy, which provides pharmacy services to long-term healthcare facilities, raised $112 million in its U.S. initial public offering on Wednesday.
Guardian Pharmacy Services' IPO Valuation Looks Pricey
Guardian Pharmacy Services has filed proposed terms for a $101 million U.S. IPO. The company focuses on providing outsourced pharmacy services to long-term healthcare facilities, targeting assisted living, skilled nursing, and behavioral health facilities. Guardian's financial performance has declined somewhat, with increased liabilities and a slowing growth rate.
Guardian Pharmacy targets up to $974 mln valuation in US IPO
Guardian Pharmacy Services said on Monday it was targeting a valuation as much as $973.5 million in its initial public offering in the United States.
